Renal protective role of Xiexin decoction with multiple active ingredients involves inhibition of inflammation through downregulation of the nuclear factor-κB pathway in diabetic rats

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Wu, Jia Sheng ^a   Shi, Rong ^a   Zhong, Jie ^a   Lu, Xiong ^a   Ma, Bing Liang ^a   Wang, Tian Ming ^a   Zan, Bin ^a   Ma, Yue Ming ^a   Cheng, Neng Neng ^b   Qiu, Fu Rong ^c  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c Shanghai Shuguang Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; BAICALEIN; BAICALIN; BERBERINE; BETA ACTIN; CHINESE DRUG; COPTISINE; CREATININE; EMODIN; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; JATRORRHIZINE; LOSARTAN; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PALMATINE; RHEIN; STREPTOZOCIN; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WOGONIN; XIEXIN DECOCTION;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG STRUCTURE; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; KIDNEY MASS; LIMIT OF QUANTITATION; LIPID DIET; LIQUID CHROMATOGRAPHY; MALE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; STREPTOZOCIN DIABETES; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

EID: 84880882112     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/715671     Document Type: Article

References (48)

1. Scully T., Diabetes in numbers. Nature 2012 485 7398 S2 S3
2. Rossing P., Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Current Diabetes Reports 2006 6 6 479 483 2-s2.0-33845388491 10.1007/s11892-006-0083-y (Pubitemid 44896409)
3. Dunlop M., Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney International, Supplement 2000 58 77 S3 S12 2-s2.0-0033857113
4. Das Evcimen N., King G. L., The role of protein kinase C activation and the vascular complications of diabetes. Pharmacological Research 2007 55 6 498 510 2-s2.0-34250702110 10.1016/j.phrs.2007.04.016 (Pubitemid 46962309)
5. Sourris K. C., Morley A. L., Koitka A., Samuel P., Coughlan M. T., Penfold S. A., Thomas M. C., Bierhaus A., Nawroth P. P., Yamamoto H., Allen T. J., Walther T., Hussain T., Cooper M. E., Forbes J. M., Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. Diabetologia 2010 53 11 2442 2451 2-s2.0-77957685095 10.1007/s00125-010-1837-2
6. Yamagishi S.-I., Matsui T., Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxidative Medicine and Cellular Longevity 2010 3 2 101 108 2-s2.0-77953729130 10.4161/oxim.3.2.11148
7. Lim A. K., Tesch G. H., Inflammation in diabetic nephropathy. Mediators of Inflammation 2012 2012 146 154
8. Navarro-González J. F., Mora-Fernández C., de Fuentes M. M., García-Pérez J., Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nature Reviews Nephrology 2011 7 6 327 340 2-s2.0-79957874666 10.1038/nrneph.2011.51
9. Bakris G. L., Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clinic Proceedings 2011 86 5 444 456 2-s2.0-79955668545 10.4065/mcp.2010.0713
10. Van Buren P. N., Toto R., Current update in the management of diabetic nephropathy. Current Diabetes Reviews 2013 9 1 62 77
11. Vejakama P., Thakkinstian A., Lertrattananon D., Ingsathit A., Ngarmukos C., Attia J., Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 2012 55 3 566 578 2-s2.0-84856703024 10.1007/s00125-011-2398-8
12. Heerspink H. J. L., de Zeeuw D., The kidney in type 2 diabetes therapy. Review of Diabetic Studies 2011 8 3 392 402 2-s2.0-84856002173 10.1900/RDS.2011.8.392
13. Tong X. L., Dong L., Chen L., Zhen Z., Treatment of diabetes using traditional chinese medicine: past, present and future. American Journal of Chinese Medicine 2012 40 5 877 886
14. Zhao H.-L., Sui Y., Qiao C.-F., Yip K. Y., Leung R. K. K., Tsui S. K. W., Lee H.-M., Wong H. K. T., Zhu X., Siu J. J., He L., Guan J., Liu L.-Z., Xu H.-X., Tong P. C. Y., Chan J. C. N., Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression. Diabetes 2012 61 4 933 943 2-s2.0-84859542680 10.2337/db11-1164
15. Shi X., Lu X. G., Zhan L. B., Qi X., Liang L. N., Hu S. Y., Yan Y., Zhao S. Y., Sui H., Zhang F. L., The effects of the Chinese medicine ZiBu PiYin recipe on the hippocampus in a rat model of diabetes-associated cognitive decline: a proteomic analysis. Diabetologia 2011 54 7 1888 1899 2-s2.0-79959732691 10.1007/s00125-011-2147-z
16. Lin C.-C., Lin L.-T., Yen M.-H., Cheng J.-T., Hsing C.-H., Yeh C.-H., Renal protective effect of Xiao-Chai-Hu-Tang on diabetic nephropathy of type 1-diabetic mice. Evidence-based Complementary and Alternative Medicine 2012 2012 11 2-s2.0-84859767937 10.1155/2012/984024 984024
17. Zhang H. J., Li P., Burczynski F. J., Attenuation of diabetic nephropathy in otsuka long-evans tokushima fatty (OLETF) rats with a combination of Chinese herbs (Tangshen Formula). Evidence-Based Complementary and Alternative Medicine 2011 2011 8 10.1155/2011/613737 613737
18. Sun S. M., Bei Ji Qian Jin Yao Fang 1999 Beijing, China Ancient Books Press of Traditional Chinese Medicine
19. Zhang S. Y., Traditional Herbal Formula of Pharmacologist Sun Si Miao 1999 Xi'an, China The World Book Press
20. Wu J.-S., Lu X., Ma Y.-M., Zhang N., Effect of Xiexin Decoction on early diabetic nephropathy in diabetic rats. Chinese Traditional and Herbal Drugs 2010 41 1 73 77 2-s2.0-77950538394
21. Lo Y. C., Lin Y. L., Yu K. L., Lai Y. H., Wu Y. C., Ann L. M., Chen I. J., San-Huang-Xie-Xin-Tang attenuates inflammatory responses in lipopolysaccharide-exposed rat lungs. Journal of Ethnopharmacology 2005 101 1-3 68 74 2-s2.0-24644459472 10.1016/j.jep.2005.03.015 (Pubitemid 41265603)
22. Shih Y.-T., Wu D.-C., Liu C.-M., Yang Y.-C., Chen I.-J., Lo Y.-C., San-Huang-Xie-Xin-Tang inhibits Helicobacter pylori-induced inflammation in human gastric epithelial AGS cells. Journal of Ethnopharmacology 2007 112 3 537 544 2-s2.0-34347364722 10.1016/j.jep.2007.04.015 (Pubitemid 47016885)
23. Ma B.-L., Ma Y.-M., Yan D.-M., Zhou H., Shi R., Wang T.-M., Yang Y., Wang C.-H., Zhang N., Effective constituents in Xiexin Decoction for anti-inflammation. Journal of Ethnopharmacology 2009 125 1 151 156 2-s2.0-67651098678 10.1016/j.jep.2009.05.035
24. Zan B., Shi R., Wang T., Wu J., Ma Y., Cheng N., Simultaneous quantification of multiple active components from Xiexin decoction in rat plasma by LC-ESI-MS/MS: application in pharmacokinetics. Biomedical Chromatography 2011 25 7 816 826 2-s2.0-79958201852 10.1002/bmc.1521
25. Zhang J., Zhou F., Lu M., Pharmacokinetics-pharmacology disconnection of herbal medicines and its potential solutions with cellular pharmacokinetic- pharmacodynamic strategy. Current Drug Metabolism 2012 13 5 558 576
26. Xu C., Barchet T. M., Mager D. E., Quantitative structure-property relationships of camptothecins in humans. Cancer Chemotherapy and Pharmacology 2010 65 2 325 333 2-s2.0-71349085110 10.1007/s00280-009-1037-2
27. Deeb O., Jawabreh S., Goodarzi M., Exploring QSARs of vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitors by MLR, PLS and PC-ANN. Current Pharmaceutical Design 3 19 12 2237 2244
28. Xu X., Zhang W., Huang C., A novel chemometric method for the prediction of human oral bioavailability. International Journal of Molecular Sciences 2012 13 6 6964 6982
29. Xue L., Wang Y., Liu L., Zhao L., Han T., Zhang Q., Qin L., A1HNMR-based metabonomics study of postmenopausal osteoporosis and intervention effects of er-xian decoction in ovariectomized rats. International Journal of Molecular Sciences 2011 12 11 7635 7651 2-s2.0-82255181737 10.3390/ijms12117635
30. Xue F., Li S., Luan J., Yuan Z., Luben R. N., Khaw K.-T., Wareham N. J., Loos R. J. F., Zhao J. H., A latent variable partial least squares path modeling approach to regional association and polygenic effect with applications to a human obesity study. PLoS ONE 2012 7 2 2-s2.0-84857575988 10.1371/journal.pone. 0031927 e31927
31. Shi R., Ma Y.-M., Ye F.-Y., Zhang N., Wang T.-M., Change of anthraquinones in Xiexin Decoction with different compatibilities. Chinese Traditional and Herbal Drugs 2007 38 9 1327 1330 2-s2.0-35648994901 (Pubitemid 350019979)
32. Shi R., Ma Y.-M., Zhang N., Ye F.-Y., Wang T.-M., Study on contents of alkaloids and flavonoids in Xiexin Decoction with different combinations. Chinese Pharmaceutical Journal 2007 42 23 1770 1773 2-s2.0-37549071419
33. Ka S. M., Yeh Y. C., Huang X. R., Chao T. K., Hung Y. J., Yu C. P., Lin T. J., Wu C. C., Lan H. Y., Chen A., Kidney-targeting Smad7 gene transfer inhibits renal TGF- β /MAD homologue (SMAD) and nuclear factor b (NF-κB) signalling pathways, and improves diabetic nephropathy in mice. Diabetologia 2012 55 2 509 519 2-s2.0-84856718373 10.1007/s00125-011-2364-5
34. Barutta F., Corbelli A., Mastrocola R., Gambino R., Marzo V. D., Pinach S., Rastaldi M. P., Perin P. C., Gruden G., Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes 2010 59 4 1046 1054 2-s2.0-77951157731 10.2337/db09-1336
35. 2+/calmodulin- dependent protein kinase II α (Thr286Asp) transgenic mice. Diabetologia 2011 54 11 2953 2962 2-s2.0-80054700053 10.1007/s00125-011-2270-x
36. Gu J., Zhang H., Chen L., Xu S., Yuan G., Xu X., Drug-target network and polypharmacology studies of a Traditional Chinese Medicine for type II diabetes mellitus. Computational Biology and Chemistry 2011 35 5 293 297 2-s2.0-80052088034 10.1016/j.compbiolchem.2011.07.003
37. Gao Q., Qin W.-S., Jia Z.-H., Zheng J.-M., Zeng C.-H., Li L.-S., Liu Z.-H., Rhein improves renal lesion and ameliorates dyslipidemia in db/db mice with diabetic nephropathy. Planta Medica 2010 76 1 27 33 2-s2.0-74349098549 10.1055/s-0029-1185948
38. Wang J., Huang H., Liu P., Tang F., Qin J., Huang W., Chen F., Guo F., Liu W., Yang B., Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats. European Journal of Pharmacology 2006 553 1 3 297 303 2-s2.0-33751172922 10.1016/j.ejphar.2006.08. 087 (Pubitemid 44779584)
39. Su N., Zhao P., She Y., Study on effects of baicalin on the repaired of injured podocytes in diabetic nephropathy rats. China Journal of Chinese Medcine 2008 26 158 803 805
40. Wu D., Wen W., Qi C.-L., Zhao R.-X., Lü J.-H., Zhong C.-Y., Chen Y.-Y., Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin. Phytomedicine 2012 19 8-9 712 718 10.1016/j.phymed.2012.03.003 2-s2.0-84859168971 10.1016/j.phymed.2012.03.003
41. Liu W., Zhang X., Liu P., Shen X., Lan T., Li W., Jiang Q., Xie X., Huang H., Effects of berberine on matrix accumulation and NF-kappa B signal pathway in alloxan-induced diabetic mice with renal injury. European Journal of Pharmacology 2010 638 1-3 150 155 2-s2.0-77953537219 10.1016/j.ejphar.2010.04. 033
42. Xie W., Gu D., Li J., Cui K., Zhang Y., Effects and action mechanisms of berberine and rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. PLoS ONE 2011 6 9 2-s2.0-80052479571 10.1371/journal.pone.0024520 e24520
43. Zhang X., Zhao Y., Zhang M., Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One 2012 7 8 10.1371/journal.pone.0042529 e42529
44. Louro T. M., Matafome P. N., Nunes E. C., Xavier Da Cunha F., Seiça R. M., Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats. European Journal of Pharmacology 2011 653 1-3 89 94 2-s2.0-78651518054 10.1016/j.ejphar.2010.11.029
45. Ishibashi Y., Matsui T., Takeuchi M., Yamagishi S., Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression. Hormone and Metabolic Research 2012 44 12 891 895
46. Liu J. J., Gan H., Du X. G., Effect of losartan on renal inflammation reaction and podocyte injury in the kidney of diabetic rat. Chinese Journal of Nephrology 2007 23 3 189 193
47. Zheng X. J., Shi S. L., Effects of losartan on renal NF-κB expression in diabetic rats. Journal of Huazhong University of Science and Technology 2002 31 2 178 180
48. Lee M. Y., Shim M. S., Kim B. H., Effects of spironolactone and losartan on diabetic nephropathy in a type 2 diabetic rat model. Diabetes Metabolism Journal 2011 35 2 130 137